Absorption and Systematic Pharmacokinetics of IDP-123 Lotion in Comparison With Tazorac Cream

Key Inclusion Criteria: * Male or female, at least 9 years of age (at least 12 years of age for Tazorac Cream). * Verbal and written informed consent must be obtained. Subjects less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if the subject reaches age of consent during the study they should be re-consented at the next study visit). * Subject must have a score of 3 (moderate) or 4 (severe) on the Evaluator's Global Severity assessment at the screening and baseline visit. * Subjects with facial acne inflammatory lesion count no less than 20 but no more than 40. * Subjects with facial acne non-inflammatory lesions count no less than 20 but no more than 100. Key Exclusion Criteria: * Use of an investigational drug or device within 30 days of enrollment or participation in a research study concurrent with this study. * Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobate, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gram-negative folliculitis, dermatitis, eczema. * Any underlying disease or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive. * Subjects with a facial beard or mustache that could interfere with the study assessments. * Subjects with more than 2 facial nodules.